3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Conditions
Colorectal Neoplasms
2
Urinary Bladder Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrent Platinum Resistant Ovarian Cancer
1
Neoplasm Metastasis
1
Carcinoma
1
Interventions
pembrolizumab
40
Gemcitabine
37
Cisplatin
28
Carboplatin
17
enfortumab vedotin
15
Nivolumab
15
Mitomycin
14
atezolizumab
13
avelumab
12
Docetaxel
10
vinflunine
9
5-aminolevulinic acid hexyl ester
9
apaziquone
8
Paclitaxel
8
BCG Vaccine
7
durvalumab
6
Fluorouracil
6
Cystectomy
6
sacituzumab govitecan
4
Surgical Procedures, Operative
4
Drug Therapy
4
vofatamab
3
valrubicin
3
tisotumab vedotin
3
erdafitinib
3
cemiplimab
3
belinostat
3
Therapeutic Uses
3
Ramucirumab
3
Cystoscopy
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Urinary Bladder Neoplasms
×
enadenotucirev
×
Clear all
NCT02028442
2020-03-12
EVOLVE
Akamis Bio
Phase 1/2
Completed
61 enrolled